查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1606412

去势抵抗性前列腺市场，按治疗方法、配销通路、国家和地区 - 2024-2032 年行业分析、市场规模、市场份额和预测

Castrate Resistant Prostate Market, By Therapy, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 260 Pages | 商品交期: 2-3个工作天内

价格
简介目录

报告要点

2023年，去势抵抗性摄护腺市场价值为89.0454亿美元，2024年至2032年复合年增长率为8.70%。

去势抵抗性前列腺市场-市场动态

增加前列腺癌的早期检测预计将推动市场成长。

早期检测有助于在前列腺癌的初始阶段透过雄性激素剥夺疗法 (ADT) 或替代疗法进行及时干预。然而，儘管进行了初步治疗，某些病例仍会进展为去势抵抗性前列腺癌（CRPC），但早期干预可能有助于延长患者的生存期。虽然前列腺癌可能带来重大的健康风险，但大多数被诊断出患有疾病的男性并没有屈服于这种疾病。根据美国癌症协会预测，2024 年美国前列腺癌新发病例约为 299,010 例，约 35,250 人因该疾病死亡。此外，新疗法的出现和诊断技术的进步可能会为市场扩张开闢新的途径。然而，发展中地区的意识和诊断能力有限可能会阻碍市场成长。

去势抵抗性前列腺市场 - 关键见解

根据我们的研究分析师分享的分析，预计全球市场在预测期内（2024-2032 年）每年将以 8.70% 左右的复合年增长率成长

根据治疗细分，荷尔蒙疗法是 2023 年领先的药物类别

按地区划分，北美是 2023 年的主要收入来源

去势抵抗性前列腺市场-細項分析：

全球去势抵抗性前列腺市场根据治疗、配销通路和地区进行细分。

根据治疗类型，市场分为四个不同的类别：化疗、荷尔蒙治疗、免疫疗法和放射治疗。荷尔蒙疗法在市场上占据主导地位。鑑于前列腺癌的进展主要受雄激素，特别是睾酮的影响，这种治疗形式对于去势抵抗性前列腺癌（CRPC）的治疗至关重要。

根据配销通路，市场分为四类：医院、癌症治疗中心、零售药房和线上药房。医院和癌症治疗中心在提供先进和专业护理方面继续发挥至关重要的作用，而随着越来越多的患者选择门诊治疗管理，零售和线上药局也变得越来越重要。

去势抵抗性前列腺市场 - 地理洞察

市场地域广阔，涵盖北美、拉丁美洲、欧洲、亚太地区、中东和非洲。这些领域根据对商业活动做出贡献的国家进一步分类。北美在市场扩张方面处于领先地位，这主要是由于医疗保健支出的增加和治疗选择的增加。北美地区，尤其是美国和加拿大医疗保健支出的大幅成长对 CRPC 市场的成长至关重要。医疗保健预算的增加促进了对最先进的医疗、先进的诊断工具和 CRPC 创新疗法的更多投资。根据国家卫生支出，2022 年美国医疗保健支出增长 4.1%，达到 4.5 兆美元，超过 2021 年 3.2% 的增幅，但仍远低于 2020 年 10.6% 的增幅。了市场成长的最大区域。

去势抵抗性前列腺市场-竞争格局：

去势抵抗性前列腺癌 (CRPC) 市场的特点是致力于创新疗法开发和商业化的製药和生物製药公司之间的激烈竞争。由于已有多种成熟的治疗方法，市场正在经历日益饱和，促使公司采取积极的营销和促销策略来获得更大的份额。对联合疗法、基因分析和免疫肿瘤学的重视预计将进一步影响不断变化的竞争环境。

最新进展：

2019 年9 月30 日，《新英格兰医学杂誌》发布的研究结果表明，患有转移性去势抵抗性前列腺癌(mCRPC) 的患者先前接受过多西他赛治疗，并在接受雄激素受体(AR) 治疗期间在12 个月内出现疾病进展）标靶治疗（阿比特龙或恩杂鲁胺）与接受阿比特龙加泼尼鬆或恩杂鲁胺治疗的患者相比，使用Jevtana（卡巴他赛）合併泼尼松治疗时，影像学无恶化存活期(rPFS) 显着延长。

2024 年1 月24 日，强生公司透露，新的临床和现实世界证据将在即将于1 月25 日至27 日在旧金山举行的ASCO GU 研讨会上以18 份摘要的形式提出。本公司的奉献精神推进泌尿生殖 (GU) 癌症的研究。

目录

第一章：去势抵抗性前列腺市场概述

  • 研究范围
  • 市场预估年份

第 2 章：执行摘要

  • 市场片段
    • 去势抵抗性前列腺治疗市场片段
    • 按配销通路分類的去势抵抗性前列腺市场片段
    • 去势抗性前列腺市场片段（依国家/地区）
    • 按地区分類的去势抗性前列腺市场片段
  • 竞争洞察

第 3 章：去势抵抗性摄护腺主要市场趋势

  • 去势抵抗性前列腺市场驱动因素
    • 市场驱动因素的影响分析
  • 去势抵抗性前列腺市场的限制
    • 市场限制影响分析
  • 去势抵抗性前列腺市场机会
  • 去势抵抗性前列腺市场未来趋势

第 4 章：去势抗性前列腺产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第 5 章：去势抵抗性前列腺市场：COVID-19 影响分析

  • COVID-19 之前的影响分析
  • COVID-19 后影响分析
    • 表现最佳的市场区隔
    • 边际增长部分
    • 最鬆散的部分
    • 边际损失部分

第 6 章：去势抵抗性前列腺市场格局

  • 2022 年抗去势前列腺市场占有率分析
  • 按主要製造商分類的故障数据
    • 既定玩家分析
    • 新兴玩家分析

第 7 章：去势抵抗性前列腺市场 - 透过治疗

  • 概述
    • 按疗法分類的细分市场份额分析
    • 化疗
    • 荷尔蒙疗法
    • 免疫治疗
    • 放射治疗

第 8 章：去势抵抗性前列腺市场 - 按配销通路

  • 概述
    • 按配销通路分類的细分市场份额分析
    • 医院
    • 癌症治疗中心
    • 零售药局
    • 网路药局

第 9 章：去势抵抗性前列腺市场 - 按地理位置

  • 介绍
    • 按地理位置分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美抗去势前列腺主要製造商
    • 北美市场规模和预测（按国家）
    • 北美市场规模和预测（按治疗）
    • 北美市场规模和预测（按配销通路）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲抗去势前列腺主要製造商
    • 欧洲市场规模和预测（按国家）
    • 欧洲市场规模与预测（按治疗）
    • 欧洲市场规模和预测（按配销通路）
    • 德国
    • 义大利
    • 英国
    • 法国
    • 俄罗斯
    • 荷兰
    • 瑞典
    • 波兰
    • 欧洲其他地区
  • 亚太地区 (APAC)
    • 概述
    • 亚太地区抗去势前列腺主要製造商
    • 亚太地区市场规模与预测（按国家）
    • 亚太地区市场规模与预测（按治疗）
    • 亚太地区市场规模和预测（按配销通路）
    • 印度
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 泰国
    • 印尼
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲抗去势摄护腺主要製造商
    • 拉丁美洲市场规模与预测（按国家）
    • 拉丁美洲市场规模与预测（按疗法）
    • 拉丁美洲市场规模和预测（按配销通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲
    • 概述
    • 中东和非洲去势抗性前列腺主要製造商
    • 中东和非洲市场规模及预测（按国家）
    • 中东和非洲市场规模和预测（按疗法）
    • 中东和非洲市场规模及预测（按配销通路）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 的其余部分

第 10 章：主要供应商分析 - 抗去势前列腺产业

  • 竞争仪表板
  • 公司简介
    • Sanofi
    • Johnson & Johnson Services, Inc.
    • Pfizer, Inc.
    • Astellas Pharma, Inc.
    • Bayer AG
    • Phinergy
    • Others

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV4182

REPORT HIGHLIGHT

The Castrate-Resistant Prostate Market was valued at USD 8,904.54 million in 2023 and expanded at a CAGR of 8.70% from 2024 to 2032.

Castration-resistant prostate cancer (CRPC) represents an advanced stage of prostate cancer. In cases of CRPC, the cancer exhibits limited responsiveness to therapies aimed at reducing testosterone levels. Indicators of progression, such as an increasing prostate-specific antigen (PSA) level, can occur despite diminished testosterone. Generally, CRPC is associated with a less favorable prognosis than hormone-sensitive prostate cancer, as it tends to be more aggressive and prone to metastasis. Current research efforts are directed toward elucidating the mechanisms underlying resistance to androgen deprivation and creating innovative treatment options that target these pathways.

Castrate Resistant Prostate Market- Market Dynamics

Increasing early detection of prostate cancer is expected to propel market growth.

Early detection facilitates prompt intervention through androgen deprivation therapies (ADT) or alternative treatments during the initial stages of prostate cancer. Nevertheless, certain cases will progress to castration-resistant prostate cancer (CRPC) despite initial therapies, yet early intervention may contribute to prolonged patient survival. While prostate cancer can pose significant health risks, the majority of men diagnosed with the disease do not succumb to it. According to the American Cancer Society, projections for prostate cancer in the United States for 2024 indicate approximately 299,010 new cases and around 35,250 fatalities attributed to the disease. Additionally, the emergence of novel therapies and advancements in diagnostic technologies may open new pathways for market expansion. However, limited awareness and diagnostic capabilities in developing regions could hinder market growth.

Castrate Resistant Prostate Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 8.70% over the forecast period (2024-2032)

Based on Therapy segmentation, Hormonal Therapy was the leading Drug Class in 2023

Based on region, North America was the leading revenue generator in 2023

Castrate Resistant Prostate Market- Segmentation Analysis:

The Global Castrate Resistant Prostate Market is segmented based on Therapy, Distribution channel, and Region.

The market is segmented into four distinct categories according to therapy type: Chemotherapy, Hormonal Therapy, Immunotherapy, and Radiotherapy. Hormonal Therapy holds a predominant position in the market. This form of therapy is essential in the management of Castrate-Resistant Prostate Cancer (CRPC), given that the progression of prostate cancer is primarily influenced by androgen hormones, particularly testosterone.

The market is segmented into four categories according to the Distribution Channel: Hospitals, Cancer Treatment Centers, Retail Pharmacies, and Online Pharmacies. Hospitals and cancer treatment centers continue to play a vital role in delivering advanced and specialized care, whereas retail and online pharmacies are increasingly significant as a growing number of patients opt for outpatient treatment management.

Castrate Resistant Prostate Market- Geographical Insights

This market is geographically extensive, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These areas are further categorized based on the countries contributing to business activities. North America leads in market expansion, primarily due to rising healthcare expenditures and enhanced access to treatment options. The significant increase in healthcare spending in North America, especially in the United States and Canada, is crucial to the growth of the CRPC market. Elevated healthcare budgets facilitate greater investment in state-of-the-art medical treatments, advanced diagnostic tools, and innovative therapies for CRPC. According to National Health Expenditures, healthcare spending in the U.S. rose by 4.1% to USD 4.5 trillion in 2022, outpacing the 3.2% increase observed in 2021, although it remains considerably lower than the 10.6% surge in 2020. Europe ranks as the second-largest region for market growth, driven by a growing preference for outpatient care.

Castrate Resistant Prostate Market- Competitive Landscape:

The market for castrate-resistant prostate cancer (CRPC) is marked by significant competition among pharmaceutical and biopharmaceutical companies dedicated to the development and commercialization of innovative therapies. As numerous established treatments are already present, the market is experiencing a growing saturation, prompting companies to engage in vigorous marketing and promotional strategies to secure a larger share. The emphasis on combination therapies, genetic profiling, and immuno-oncology is expected to further influence the evolving competitive environment.

Recent Developments:

On September 30, 2019, findings released in the New England Journal of Medicine indicated that patients suffering from metastatic castration-resistant prostate cancer (mCRPC) who had previously undergone treatment with docetaxel and exhibited disease progression within 12 months while on an androgen receptor (AR)-targeted therapy (either abiraterone or enzalutamide) demonstrated a notably extended radiographic progression-free survival (rPFS) when treated with Jevtana (cabazitaxel) in combination with prednisone, in comparison to those receiving abiraterone plus prednisone or enzalutamide.

On January 24, 2024, Johnson & Johnson revealed that new clinical and real-world evidence will be presented in 18 abstracts at the upcoming ASCO GU Symposium, scheduled to take place in San Francisco from January 25 to 27. This announcement underscores the Company's dedication to advancing the research in genitourinary (GU) cancers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CASTRATE-RESISTANT PROSTATE MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Sanofi
  • Johnson & Johnson Services, Inc.
  • Pfizer, Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • Phinergy
  • Others

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY THERAPY- MARKET ANALYSIS, 2019 - 2032

  • Chemotherapy
  • Hormonal Therapy
  • Immunotherapy
  • Radiotherapy

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Cancer Treatment Centers
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL CASTRATE RESISTANT PROSTATE MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Castrate Resistant Prostate Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Castrate Resistant Prostate Market Snippet by Therapy
    • 2.1.2. Castrate Resistant Prostate Market Snippet by Distribution Channel
    • 2.1.3. Castrate Resistant Prostate Market Snippet by Country
    • 2.1.4. Castrate Resistant Prostate Market Snippet by Region
  • 2.2. Competitive Insights

3. Castrate Resistant Prostate Key Market Trends

  • 3.1. Castrate Resistant Prostate Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Castrate Resistant Prostate Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Castrate Resistant Prostate Market Opportunities
  • 3.4. Castrate Resistant Prostate Market Future Trends

4. Castrate Resistant Prostate Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Castrate Resistant Prostate Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Castrate Resistant Prostate Market Landscape

  • 6.1. Castrate Resistant Prostate Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Castrate Resistant Prostate Market - By Therapy

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Therapy, 2022 & 2030 (%)
    • 7.1.2. Chemotherapy
    • 7.1.3. Hormonal Therapy
    • 7.1.4. Immunotherapy
    • 7.1.5. Radiotherapy

8. Castrate Resistant Prostate Market - By Distribution Channel

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2022 & 2030 (%)
    • 8.1.2. Hospitals
    • 8.1.3. Cancer Treatment Centers
    • 8.1.4. Retail Pharmacies
    • 8.1.5. Online Pharmacies

9. Castrate Resistant Prostate Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Castrate Resistant Prostate Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Castrate Resistant Prostate Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Castrate Resistant Prostate Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Castrate Resistant Prostate Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Castrate Resistant Prostate Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Therapy, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Castrate Resistant Prostate Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Sanofi
    • 10.2.2. Johnson & Johnson Services, Inc.
    • 10.2.3. Pfizer, Inc.
    • 10.2.4. Astellas Pharma, Inc.
    • 10.2.5. Bayer AG
    • 10.2.6. Phinergy
    • 10.2.7. Others

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us